Search

Your search keyword '"Bonnemain B"' showing total 240 results
Start Over Author "Bonnemain B"
240 results on '"Bonnemain B"'

3. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Author

Abadie, V., Achour, C., Ader, F., Alchaar, H., Alkhedr, A., Andreux, F., Androdias, G., Arjmand, R., Audoin, B., Audry, D., Aufauvre, D., Autreaux, C., Ayrignac, X., Bailbe, M., Benazet, M., Bensa, C., Bensmail, D., Berger, E., Bernady, P., Bertagna, Y., Biotti, D., Blanchard-Dauphin, A., Bonenfant, J., Bonnan, M., Bonnemain, B., Borgel, F., Botelho-Nevers, E., Boucly, S., Bourre, B., Boutière, C., Branger, P., Brassat, D., Bresch, S., Breuil, V., Brochet, B., Brugeilles, H., Bugnon, P., Cabre, P., Camdessanché, J.-P., Carra-Dalière, C., Casez, O., Chamouard, J.-M., Chassande, B., Chataignier, P., Chbicheb, M., Chenet, A., Ciron, J., Clavelou, P., Cohen, M., Colamarino, R., Collongues, N., Coman, I., Corail, P.-R., Courtois, S., Coustans, M., Creange, A., Creisson, E., Daluzeau, N., Davenas, C., De Seze, J., Debouverie, M., Depaz, R., Derache, N., Divio, L., Douay, X., Dulau, C., Durand-Dubief, F., Edan, G., Elias, Z., Fagniez, O., Faucher, M., Faucheux, J.-M., Fournier, M., Gagneux-Brunon, A., Gaida, P., Galli, P., Gallien, P., Gaudelus, J., Gault, D., Gayou, A., Genevray, M., Gentil, A., Gere, J., Gignoux, L., Giroux, M., Givron, P., Gout, O., Grimaud, J., Guennoc, A.-M., Hadhoum, N., Hautecoeur, P., Heinzlef, O., Jaeger, M., Jeannin, S., Kremer, L., Kwiatkowski, A., Labauge, P., Labeyrie, C., Lachaud, S., Laffont, I., Lanctin-Garcia, C., Lannoy, J., Lanotte, L., Laplaud, D., Latombe, D., Lauxerois, M., Le Page, E., Lebrun-Frenay, C., Lejeune, P., Lejoyeux, P., Lemonnier, B., Leray, E., Loche, C.-M., Louapre, C., Lubetzki, C., Maarouf, A., Mada, B., Magy, L., Maillart, E., Manchon, E., Marignier, R., Marque, P., Mathey, G., Maurousset, A., Mekies, C., Merienne, M., Michel, L., Milor, A.-M., Moisset, X., Montcuquet, A., Moreau, T., Morel, N., Moussa, M., Naudillon, J.-P., Normand, M., Olive, P., Ouallet, J.-C., Outteryck, O., Pacault, C., Papeix, C., Patry, I., Peaureaux, D., Pelletier, J., Pichon, B., Pittion, S., Planque, E., Pouget, M.-C., Pourcher, V., Radot, C., Robert, I., Rocher, F., Ruet, A., Saint-Val, C., Salle, J.-Y., Salmon, A., Sartori, E., Schaeffer, S., Stankhof, B., Taithe, F., Thouvenot, E., Tizon, C., Tourbah, A., Tourniaire, P., Vaillant, M., Vermersch, P., Vidil, S., Wahab, A., Warter, M.-H., Wiertlewski, S., Wiplosz, B., Wittwer, B., Zaenker, C., Zephir, H., Lebrun, C., and Vukusic, S.

Published
2019
Full Text
View/download PDF

17. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Author

Lebrun, C., primary, Vukusic, S., additional, Abadie, V., additional, Achour, C., additional, Ader, F., additional, Alchaar, H., additional, Alkhedr, A., additional, Andreux, F., additional, Androdias, G., additional, Arjmand, R., additional, Audoin, B., additional, Audry, D., additional, Aufauvre, D., additional, Autreaux, C., additional, Ayrignac, X., additional, Bailbe, M., additional, Benazet, M., additional, Bensa, C., additional, Bensmail, D., additional, Berger, E., additional, Bernady, P., additional, Bertagna, Y., additional, Biotti, D., additional, Blanchard-Dauphin, A., additional, Bonenfant, J., additional, Bonnan, M., additional, Bonnemain, B., additional, Borgel, F., additional, Botelho-Nevers, E., additional, Boucly, S., additional, Bourre, B., additional, Boutière, C., additional, Branger, P., additional, Brassat, D., additional, Bresch, S., additional, Breuil, V., additional, Brochet, B., additional, Brugeilles, H., additional, Bugnon, P., additional, Cabre, P., additional, Camdessanché, J.-P., additional, Carra-Dalière, C., additional, Casez, O., additional, Chamouard, J.-M., additional, Chassande, B., additional, Chataignier, P., additional, Chbicheb, M., additional, Chenet, A., additional, Ciron, J., additional, Clavelou, P., additional, Cohen, M., additional, Colamarino, R., additional, Collongues, N., additional, Coman, I., additional, Corail, P.-R., additional, Courtois, S., additional, Coustans, M., additional, Creange, A., additional, Creisson, E., additional, Daluzeau, N., additional, Davenas, C., additional, De Seze, J., additional, Debouverie, M., additional, Depaz, R., additional, Derache, N., additional, Divio, L., additional, Douay, X., additional, Dulau, C., additional, Durand-Dubief, F., additional, Edan, G., additional, Elias, Z., additional, Fagniez, O., additional, Faucher, M., additional, Faucheux, J.-M., additional, Fournier, M., additional, Gagneux-Brunon, A., additional, Gaida, P., additional, Galli, P., additional, Gallien, P., additional, Gaudelus, J., additional, Gault, D., additional, Gayou, A., additional, Genevray, M., additional, Gentil, A., additional, Gere, J., additional, Gignoux, L., additional, Giroux, M., additional, Givron, P., additional, Gout, O., additional, Grimaud, J., additional, Guennoc, A.-M., additional, Hadhoum, N., additional, Hautecoeur, P., additional, Heinzlef, O., additional, Jaeger, M., additional, Jeannin, S., additional, Kremer, L., additional, Kwiatkowski, A., additional, Labauge, P., additional, Labeyrie, C., additional, Lachaud, S., additional, Laffont, I., additional, Lanctin-Garcia, C., additional, Lannoy, J., additional, Lanotte, L., additional, Laplaud, D., additional, Latombe, D., additional, Lauxerois, M., additional, Le Page, E., additional, Lebrun-Frenay, C., additional, Lejeune, P., additional, Lejoyeux, P., additional, Lemonnier, B., additional, Leray, E., additional, Loche, C.-M., additional, Louapre, C., additional, Lubetzki, C., additional, Maarouf, A., additional, Mada, B., additional, Magy, L., additional, Maillart, E., additional, Manchon, E., additional, Marignier, R., additional, Marque, P., additional, Mathey, G., additional, Maurousset, A., additional, Mekies, C., additional, Merienne, M., additional, Michel, L., additional, Milor, A.-M., additional, Moisset, X., additional, Montcuquet, A., additional, Moreau, T., additional, Morel, N., additional, Moussa, M., additional, Naudillon, J.-P., additional, Normand, M., additional, Olive, P., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pacault, C., additional, Papeix, C., additional, Patry, I., additional, Peaureaux, D., additional, Pelletier, J., additional, Pichon, B., additional, Pittion, S., additional, Planque, E., additional, Pouget, M.-C., additional, Pourcher, V., additional, Radot, C., additional, Robert, I., additional, Rocher, F., additional, Ruet, A., additional, Saint-Val, C., additional, Salle, J.-Y., additional, Salmon, A., additional, Sartori, E., additional, Schaeffer, S., additional, Stankhof, B., additional, Taithe, F., additional, Thouvenot, E., additional, Tizon, C., additional, Tourbah, A., additional, Tourniaire, P., additional, Vaillant, M., additional, Vermersch, P., additional, Vidil, S., additional, Wahab, A., additional, Warter, M.-H., additional, Wiertlewski, S., additional, Wiplosz, B., additional, Wittwer, B., additional, Zaenker, C., additional, and Zephir, H., additional

Published
2019
Full Text
View/download PDF

21. Gd-DOTA

Author

Le Mignon Mm, Warrington S, Chambon C, Davies R, and Bonnemain B

Subjects
Adult, Male, medicine.medical_specialty, Gadolinium, Urology, Contrast Media, Renal function, chemistry.chemical_element, Animal data, Interstitial space, Pharmacokinetics, Heterocyclic Compounds, Organometallic Compounds, medicine, Humans, Tissue Distribution, Radiology, Nuclear Medicine and imaging, medicine.diagnostic_test, Meglumine, Chemistry, General Medicine, Magnetic Resonance Imaging, Tolerability, Serum iron, medicine.drug
Abstract

The pharmacokinetics of Gd-DOTA meglumine in humans were evaluated in six healthy male volunteers. The agent was injected intravenously at 0.1 mmol/kg over approximately 2 minutes. Its behavior was found to be similar to that of urographic and angiographic iodinated contrast media with a plasma elimination half-life of 91 +/- 14 minutes (mean +/- standard deviation [SD]), a small distribution volume of 171.0 +/- 19.7 mL/kg and rapid urinary excretion. The results suggest rapid passive extravascular diffusion of gadolinium (Gd)-DOTA in the interstitial space without intracellular penetration, followed by a rapid urinary excretion via glomerular filtration. Furthermore, the results are consistent with animal data that showed that the compound does not cross the normal blood brain barrier. Its plasma pharmacokinetics appeared to be similar to those reported for Gd-DTPA. No relevant biological effects were seen with Gd-DOTA, especially in regard to serum iron and bilirubin levels.

Published
1990

22. Accès aux soins, qualité de vie et sclérose en plaques dans les Pays de la Loire : étude de réseau professionnel (RESEP-Loire)

Author

Tanguy, E., primary, Wiertlewski, S., additional, Nicolas-Chouet, C., additional, Bernard, I., additional, Bernier, C., additional, Bertout, P., additional, Bodic, P., additional, Bonnemain, B., additional, Desjobert, S., additional, Kieny, P., additional, Lejeune, P., additional, Moreau, C., additional, Pavillon, M.-T., additional, Villard, A., additional, and Le Fort, M., additional

Published
2011
Full Text
View/download PDF

23. Access to healthcare, quality of life and multiple sclerosis in the Pays de la Loire region: A professional network-study (RESEP-Loire)

Author

Tanguy, E., primary, Wiertlewski, S., additional, Nicolas-Chouet, C., additional, Bernard, I., additional, Bernier, C., additional, Bertout, P., additional, Bodic, P., additional, Bonnemain, B., additional, Desjobert, S., additional, Kieny, P., additional, Lejeune, P., additional, Moreau, C., additional, Pavillon, T., additional, Villard, A., additional, and Le Fort, M., additional

Published
2011
Full Text
View/download PDF

32. Carboxymethyldextran-A2-Gd-DOTA enhancement patterns in the abdomen and pelvis in an animal model.

Author

Daldrup-Link, Heike E., Link, Thomas M., Möller, Harald E., Wiedermann, Dirk, Bonnemain, Bruno, Corot, Claire, Rummeny, Ernst J., Daldrup-Link, H E, Link, T M, Möller, H E, Wiedermann, D, Bonnemain, B, Corot, C, and Rummeny, E J

Subjects
ABDOMINAL diseases, PELVIS, BODY weight, TISSUES, BONE marrow, MEDICAL imaging systems, PELVIC anatomy, ABDOMEN, ANALYSIS of variance, ANIMAL experimentation, BIOLOGICAL models, COMPARATIVE studies, DIAGNOSTIC imaging, MAGNETIC resonance imaging, RESEARCH methodology, MEDICAL cooperation, ORGANOMETALLIC compounds, RABBITS, RESEARCH, EVALUATION research, CONTRAST media
Abstract

The aim of this study was to assess MR signal enhancement patterns of carboxymethyldextran (CMD)-A2-Gd-DOTA, a new macromolecular contrast agent, in the abdomen and pelvis of New Zealand white rabbits. Nine New Zealand white rabbits underwent MRI before and following injection of 0.05 mmol/kg body weight (bw) CMD-A2-Gd-DOTA (52.1 kDa), using turbo FLASH-, dynamic FLASH 60 degrees-, T1- and T2-weighted spin-echo and turbo spin-echo sequences up to 10 days p.i. Changes in blood and tissue signal intensities (deltaSI) and relaxation rates (deltaR1) were calculated. Differences between pre- and post-contrast MRI data were compared using the Scheffé test. CMD-A2-Gd-DOTA demonstrated significant blood-pool enhancement and significant tissue enhancement on T1-weighted images, whereas no significant signal changes were observed on T2-weighted images (P < 0.05). Kidney parenchyma, pelvis and bladder demonstrated a subsequent enhancement, resembling renal elimination of the majority of the contrast agent. Liver parenchyma demonstrated a slow, delayed decay of the contrast enhancement due to storage and biodegradation of larger subfractions of the contrast agent. All tissue signal intensities were back to baseline 10 days p.i. CMD-A2-Gd-DOTA is a new macromolecular contrast agent with blood-pool effect, significant signal enhancement of abdominal organs and pelvic bone marrow, partial storage in the liver and baseline tissue signal intensities by 10 days p.i. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

33. Niosomes as carriers of radiopaque contrast agents for X-ray imaging.

Author

Muller, D., Foulon, M., Bonnemain, B., and Vandamme, Th. F.

Subjects
SURFACE active agents, CONTRAST media, X-rays
Abstract

Non-ionic surfactant vesicles (niosomes) are considered as carriers of iobitridol, a diagnostic agent used for X-ray imaging. The niosomes, with a diameter between 150 and 175 nm, are prepared using the film-hydration method followed by sonication. These vesicles were obtained with appropriate mixtures of D-alpha tocopheryl polyethylene glycol 1000 succinate, polyoxyethylene glycol 4000 stearate, sorbitan monostearate, cholesterol and dicetylphosphate. Methods allowing the increase of the rate of encapsulation and the stability of the vesicles were carried out. In addition to the study of the formulation of the vesicles, the physico-chemical and morphological properties of the vesicles have been studied. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

39. Biodegradable cross-linked albumin microcapsules for embolization

Author

Bonnemain B, Fickat R, Samaille Jp, Jean-Pierre Benoit, Madoulé P, and S. Benita

Subjects
medicine.medical_specialty, Materials science, Drug Compounding, medicine.medical_treatment, Phthalic Acids, Pharmaceutical Science, Capsules, Bioengineering, Kidney, chemistry.chemical_compound, Dogs, Renal Artery, Colloid and Surface Chemistry, Acyl chloride, medicine, Animals, Embolization, Physical and Theoretical Chemistry, Serum Albumin, Chromatography, Organic Chemistry, Albumin, Embolization, Therapeutic, Interfacial polymerization, Surgery, Radiography, Biodegradation, Environmental, Cross-Linking Reagents, Membrane, chemistry, Particle size
Abstract

The interfacial polymerization process used in the present study produced individual cross-linked albumin microcapsules, the particle size of which depended on the emulsification stirring rate. The variation in cross-linking agent concentration altered the microcapsule wall properties. As shown by SEM observations, microcapsules prepared with low acyl chloride concentrations presented rippled surfaces, while the surfaces of the microcapsules prepared with high acyl chloride concentrations were smooth. It was then suggested that the membranes of the weakly cross-linked microcapsules consisted of cross-linked and denatured albumin. Embolization experiments in the dog kidney showed that the weakly cross-linked microcapsules were biodegradable within 7 days, whereas the highly cross-linked microcapsules were degraded over more than 14 days and led to prolonged ischaemia. The results of the histological experiments carried out on a further eight dogs supported the previous findings yielded by the angiographical experiments. Moreover, they indicated that no foreign body reaction occurred. The lack of this inflammatory granuloma should be attributed to the rapid biodegradation of the microcapsules which produced reversible ischaemic lesions.

Published
1984

41. Iobitridol A New Nonionic LowOsmolality Contrast Agent and Iohexol

Author

BEAUFILS, H., IDÉE, J. M., BERTHOMMIER, C., BALUT, C., BOURBOUZE, R., NIMIER, K., CHICANDRE-JOUANNEAU, C., and BONNEMAIN, B.

Abstract

To compare the histologic effects on rat tubular cells of two nonionic contrast media with equivalent osmolalities and viscosities.

Published
1995

42. Effect of Contrast Media on Whole Blood Filtrability: An in Vitro Comparative Study of Iohexol, Iopamidol and Ioxaglate on Rat Blood

Author

Le Mignon, M. M., Ducret, M. Nain Dit, Bonnemain, B., and Donadieu, A. M.

Abstract

The effects of three contrast media, iohexol, iopamidol and ioxaglate, on rat erythrocytes were compared. Three parameters representative of the rheologic properties of blood were investigated: whole blood filtrability, red cell filtrability and morphology. Whole blood and red cell filtrabilities were both measured using an erythrometer and red cell morphology was observed with an optical microscope. Iohexol and iopamidol were found to cause a significant increase in filtrability indices and to modify the shape of red blood cells. Ioxaglate had less effect on these parameters than did the other two contrast media. The chemical structure seems to be a determining factor for red cell integrity. The study of blood rheology parameters in vitro may be useful as a model predictive of observations on human blood and of hemodynamic consequences.

Published
1988
Full Text
View/download PDF

44. Bioavailability of oral vs intramuscular iodinated oil (Lipiodol UF) in healthy subjects

Author

Leverge R, Jean-Francois Bergmann, Simoneau G, Tillet Y, and Bonnemain B

Subjects
Adult, Dose-Response Relationship, Drug, Reference Values, Thyroid Gland, Administration, Oral, Biological Availability, Humans, Iodized Oil, Injections, Intramuscular, Iodine, Ultrasonography
Abstract

In order to fight against iodine deficiency, the essential cause of endemic goiter and cretinism, several health organizations promoted campaigns of iodinated oil (Lipiodol UF) administration using iodinated oil administered intramuscularly. However, it seems preferable to administer iodinated oil orally, as this is more appropriate and since the efficacy of this route has been demonstrated as well as for intramuscular route by controlled clinical trials.To assess the bioavailability of iodinated oil (Lipiodol UF) administered via two different administration routes and the safety profile of this agent.A randomized bioavailability study was performed comparing a single oral dose of 3 capsules (570 mg of iodine) vs a single intramuscular injection of 1 ml of Lipiodol UF (480 mg of iodine) in 36 healthy subjects followed for 9 months.The results show that, at these dosages, the 24 h urinary iodine values are above baseline for both oral and intramuscular administrations (im:12 months/oral: 6 months) for prolonged period of time. In terms of safety, Lipiodol, administered by im injection or orally, did not induce any undesirable effects or any alteration of thyroid function tests in this study.In conclusion, this study shows that im or oral administration of a single dose of Lipiodol provides a significant and prolonged iodine supplement. The results obtained confirm the possibility of protection of exposed populations after annual administration of an appropriate single oral dose, without inducing any clinical or laboratory adverse effects. The product, by either route of administration, has a prolonged efficacy in iodine-deficient subjects (im: 2-3 years/oral: 1 year).

Catalog

Books, media, physical & digital resources
See catalog results